File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Telbivudine: An upcoming agent for chronic hepatitis B

TitleTelbivudine: An upcoming agent for chronic hepatitis B
Authors
Issue Date2005
PublisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=7
Citation
Expert Review Of Anti-Infective Therapy, 2005, v. 3 n. 4, p. 489-494 How to Cite?
AbstractTelbivudine, the prototype member of β-L-2′-deoxynucleosides, has proven to be safe in in vitro animal and human studies. Telbivudine given for 4 weeks resulted in an 8-log reduction of woodchuck hepatitis virus DNA, and a 3.8-log reduction of hepatitis B virus DNA in human. After 52 weeks of telbivudine treatment there was an approximate 6-log reduction of hepatitis B virus DNA levels, hepatitis B virus DNA became undetectable by PCR assay in 61% of patients. Its antiviral efficacy is significantly better than lamivudine. The probability of tyrosine-methionine-aspartate-aspartate mutations at 52 weeks of telbivudine therapy is low, although still occurring in 4.5% of patients. After 96 weeks of therapy, the proportion of patients with undetectable hepatitis B virus DNA by PCR assay increased to 71%, but genotypic resistance also increased to 18.2%, with only 4.5% showing alanine aminotransferase flares. Telbivudine is probably one of the most potent antiviral agents for hepatitis B virus that will become available in the near future. © 2005 Future Drugs Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/76351
ISSN
2015 Impact Factor: 3.542
2015 SCImago Journal Rankings: 1.415
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:20:18Z-
dc.date.available2010-09-06T07:20:18Z-
dc.date.issued2005en_HK
dc.identifier.citationExpert Review Of Anti-Infective Therapy, 2005, v. 3 n. 4, p. 489-494en_HK
dc.identifier.issn1478-7210en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76351-
dc.description.abstractTelbivudine, the prototype member of β-L-2′-deoxynucleosides, has proven to be safe in in vitro animal and human studies. Telbivudine given for 4 weeks resulted in an 8-log reduction of woodchuck hepatitis virus DNA, and a 3.8-log reduction of hepatitis B virus DNA in human. After 52 weeks of telbivudine treatment there was an approximate 6-log reduction of hepatitis B virus DNA levels, hepatitis B virus DNA became undetectable by PCR assay in 61% of patients. Its antiviral efficacy is significantly better than lamivudine. The probability of tyrosine-methionine-aspartate-aspartate mutations at 52 weeks of telbivudine therapy is low, although still occurring in 4.5% of patients. After 96 weeks of therapy, the proportion of patients with undetectable hepatitis B virus DNA by PCR assay increased to 71%, but genotypic resistance also increased to 18.2%, with only 4.5% showing alanine aminotransferase flares. Telbivudine is probably one of the most potent antiviral agents for hepatitis B virus that will become available in the near future. © 2005 Future Drugs Ltd.en_HK
dc.languageengen_HK
dc.publisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=7en_HK
dc.relation.ispartofExpert Review of Anti-Infective Therapyen_HK
dc.subject.meshAntiviral Agents - chemistry - pharmacology - therapeutic useen_HK
dc.subject.meshDNA, Viral - blooden_HK
dc.subject.meshHepatitis B virus - metabolismen_HK
dc.subject.meshHepatitis B, Chronic - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMolecular Structureen_HK
dc.subject.meshNucleosides - chemistry - pharmacology - therapeutic useen_HK
dc.subject.meshPyrimidinones - chemistry - pharmacology - therapeutic useen_HK
dc.titleTelbivudine: An upcoming agent for chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1478-7210&volume=3&issue=4&spage=489&epage=94&date=2005&atitle=Telbivudine:+an+upcoming+agent+for+chronic+hepatitis+B.en_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1586/14787210.3.4.489en_HK
dc.identifier.pmid16107194en_HK
dc.identifier.scopuseid_2-s2.0-24044494254en_HK
dc.identifier.hkuros122290en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-24044494254&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume3en_HK
dc.identifier.issue4en_HK
dc.identifier.spage489en_HK
dc.identifier.epage494en_HK
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats